ViiV Healthcare

Pharma

HIV treatment from GSK, Shionogi shows positive phase 3 results

An HIV drug candidate developed under a joint venture between GlaxoSmithKline (NYSE:GSK) and Japanese pharmaceutical company Shionogi is showing promise as a contender to take on a blockbuster drug  from rival Merck (NYSE:MRK). Initial phase 3 clinical trial results for dolutegravir show the GSK-Shionogi compound matches Merck’s HIV treatment raltegravir. But dolutegravir’s advantage will be […]

News

Siemens partners with ViiV, Tocagen on new personalized medicine tests

An HIV/AIDS treatment developed by GlaxoSmithKline (NYSE:GSK) is now being studied with Siemens (NYSE:SI) to develop companion diagnostics that doctors can use to select patients appropriate for the treatment. The partnership with ViiV Healthcare, GSK’s AIDS drug joint venture with Pfizer (NYSE:PFE), will study the drug Selzentry in a phase 3 study comparing it to […]

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Pharma

GSK’s HIV drug combivir to face generic from Teva

GlaxoSmithKline‘s (NYSE:GSK) HIV treatment combivir will soon face its first competition from a generic drug. Teva Pharmaceutical Industries (NASDAQ:TEVA) has received U.S. Food and Drug Administration approval on its application to market a generic version of combivir. Combivir is a combination drug that pairs azidothymidine, also known as AZT, with another antiviral, lamivudine. The combination […]